KLTO (Klotho Neurosciences) Debt-to-EBITDA : -0.01 (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Klotho Neurosciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Klotho Neurosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.15 Mil. Klotho Neurosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. Klotho Neurosciences's annualized EBITDA for the quarter that ended in Sep. 2024 was $-11.66 Mil. Klotho Neurosciences's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was -0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Klotho Neurosciences's Debt-to-EBITDA or its related term are showing as below:

KLTO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.35 Med: -2.35 Max: -0.04
Current: -0.04

During the past 2 years, the highest Debt-to-EBITDA Ratio of Klotho Neurosciences was -0.04. The lowest was -2.35. And the median was -2.35.

KLTO's Debt-to-EBITDA is ranked worse than
100% of 270 companies
in the Biotechnology industry
Industry Median: 1.41 vs KLTO: -0.04

Klotho Neurosciences Debt-to-EBITDA Historical Data

The historical data trend for Klotho Neurosciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Klotho Neurosciences Debt-to-EBITDA Chart

Klotho Neurosciences Annual Data

Trend

Dec21

Dec22

Debt-to-EBITDA

-2.35

Klotho Neurosciences Quarterly Data
	Dec21	Jun22	Dec22	Jun23	Sep23	Mar24	Jun24	Sep24
Debt-to-EBITDA	Get a 7-Day Free Trial			-1.38	-	-0.56	-2.25	-0.01

Competitive Comparison of Klotho Neurosciences's Debt-to-EBITDA

For the Biotechnology subindustry, Klotho Neurosciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Klotho Neurosciences's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Klotho Neurosciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Klotho Neurosciences's Debt-to-EBITDA falls into.

Klotho Neurosciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Klotho Neurosciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.348	+	0)	/	-0.574
	=	-2.35

Klotho Neurosciences's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.151	+	0)	/	-11.656
	=	-0.01

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.

Klotho Neurosciences (NAS:KLTO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Klotho Neurosciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Klotho Neurosciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Klotho Neurosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Klotho Neurosciences Inc (NAS:KLTO) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

13576 Walnut Street, 12th Floor, Omaha, NE, USA, 68144

Website

https://www.klothoneuro.com

Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.